Table 4.

Subgroup Analysis for Cardiovascular Mortality Associated with aTRH

	N	Deaths	Any aTRH vs. Controlled	p-interaction
Age (years)
< 45 years	579	15	NA	0.211
45–65 years	2511	117	2.13 (1.18, 3.88)
≥ 65 years	3267	418	1.23 (0.91, 1.66)
Sex
Female	3426	269	1.87 (1.26, 2.79)	0.033
Male	2931	281	1.13 (0.76, 1.69)
Race/Ethnicity
Non-Hispanic White	3432	343	1.56 (1.13, 2.15)
Non-Hispanic Black	1712	143	1.17 (0.73, 1.88)	0.583
Mexican American	1033	58	1.15 (0.38, 3.43)
Other	180	6	NA
Nonsmoker	2869	218	2.16 (1.34, 3.47)	0.075
Smoker	3481	332	1.19 (0.85, 1.65)
No Diabetes	4237	349	1.48 (1.05, 2.07)	0.746
Diabetes	2120	201	1.46 (0.94, 2.28)
No CVD	4558	261	1.68 (1.1, 2.56)	0.03
CVD	1737	282	1.35 (1, 1.81)
No Diuretic	2714	161	1.223 (0.62, 2.4)	0.818
Diuretic	3643	389	1.48 (1.04, 2.11)
No ACE-I or ARB	1705	101	1.35 (0.69, 2.62)	0.562
ACE-I or ARB	3678	260	1.7 (1.18, 2.44)
No CCBb	4117	303	1.54 (0.98, 2.43)	0.549
CCBb	2240	247	1.35 (0.93, 1.98)
No Betablocker	3811	309	1.51 (1.03, 2.22)	0.411
Betablocker	2546	241	1.4 (0.91, 2.16)
No Antihtn_otherc	5252	411	1.41 (0.98, 2.01)	0.649
Antihtn_otherc	1105	139	1.55 (0.89, 2.69)
eGFR CKDEPI Categoriesa
≥ 120	135	5	NA	0.521
90–119	1617	47	1.6 (0.57, 4.47)
60–89	2677	215	1.34 (0.88, 2.04)
45–59	929	129	1.94 (1.17, 3.2)
30–44	417	76	1.08 (0.47, 2.47)
< 30	187	38	2.33 (0.32, 16.86)
CRP (mg/dL)
< 0.22	2546	220	1.18 (0.76, 1.84)	0.582
0.22–0.99	2487	187	1.74 (1.16, 2.6)
≥ 1.00	981	109	2.17 (0.99, 4.77)
ACR
< 30	4807	310	1.79 (1.27, 2.52)	0.063
30–300	1061	142	1.31 (0.83, 2.07)
≥ 300	292	57	0.93 (0.43, 2)

Abbreviations: aTRH apparent treatment-resistant hypertension, CVD Cardiovascular Disease, eGFR CKD-EPI estimated Glomerular Filtration Rate using Chronic Kidney Disease Epidemiology Collaboration, CRP C-reactive Protein, ACR Albumin-Creatinine Ratio

^a measured in mL/min/1.73 m²

^b Calcium channel blocker

^c Other anti-hypertensive not included in the preceding anti-hypertensive classes